Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Centipeda minima* is a botanical drug derived from the whole plant of *Centipeda minima* (L.) A. Braun & Asch., a species widely recognized in Traditional Chinese Medicine as E Bu Shi Cao. It is primarily investigated for its therapeutic potential in respiratory and inflammatory conditions, most notably allergic rhinitis. The herb's pharmacological profile is characterized by its rich content of sesquiterpene lactones, such as brevilin A and arnicolide C, which exert potent anti-inflammatory and anti-allergic effects. These compounds are known to inhibit the release of inflammatory mediators (e.g., histamine, leukotrienes) and suppress the activation of the NF-kappaB signaling pathway. In clinical trials, such as those conducted by The First Affiliated Hospital of Zhejiang Chinese Medicine University, *Centipeda minima* is often administered as a topical powder or as part of a multi-herb formulation to alleviate nasal congestion and improve quality of life in patients with allergic rhinitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on centipeda minima.